Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTG/3TC Fixed Dose Formulations for Maintenance of Virological Suppression in Children With HIV
NCT04337450Phase 3Active, not recruiting
- Sponsor
- Penta Foundation
- Start
- Apr 2022
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 5
01
Overview
A Phase 3 trial of dolutegravir + lamivudine in human immunodeficiency virus infection (HIV), sponsored by Penta Foundation. Started Apr 2022; status: active, not recruiting.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04337450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04337450.